Metropolis Healthcare Limited has informed the Exchange about Transcript
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare filed the transcript of its Q4 FY25 earnings call held on May 14, 2025. The company reported FY25 revenue growth of 12% YoY, with Q4 revenue at INR 345 crores (up 10% YoY). Adjusted EBITDA for FY25 stood at INR 325 crores with a margin of 24.4%, and PAT excluding one-time costs grew 26% to INR 161 crores. The company closed three acquisitions in Q4 — Core Diagnostics (oncology, INR 105–110 cr revenue), Scientific Pathology (Agra), and DAPIC (Dehradun) — strengthening its North India presence. B2C revenue grew 17% YoY to 55% of total revenue, while TruHealth and Specialty segments grew 24% and 13% respectively. The company ended FY25 with net cash of INR 118 crores and one-time acquisition and legal costs of INR 21 crores impacted reported EBITDA.
Management guided for ~12% organic revenue growth and 100 bps organic margin expansion in FY26, with reported revenue growth of 25–26% including acquisitions. The pivot from aggressive lab expansion to productivity and collection center scaling, combined with an EPS-accretive acquisition strategy, signals a margin-led growth phase that should support steady earnings expansion for shareholders.